Clinics in Dermatology
Volume 25, Issue 6 , Pages 510-518 , November 2007

The clinical spectrum of psoriasis

References 

  1. Jackson R. The importance of being visually literate. Observations on the art and science of making a morphological diagnosis in dermatology. Arch Dermatol. 1975;111:632–636
  2. Norman GR, Rosenthal D, Brooks LR, Allen SW, Muzzin LJ. The development of expertise in dermatology. Arch Dermatol. 1989;125:1063–1068
  3. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol. 2006;126:1438–1440
  4. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469
  5. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172:298–304
  6. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–67
  7. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii3–ii8
  8. Schön MP, Henning-Boehncke W. Psoriasis. N Engl J Med. 2005;352:1899–1912
  9. Farber EM, Nall L. An appraisal of measures to prevent and control psoriasis. J Am Acad Dermatol. 1984;10:511–517
  10. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121–128
  11. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–456
  12. Bell LM, Sedlack R, Beard MC, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn 1980-1983. Arch Dermatol. 1991;127:1184–1187
  13. Naldi L, Peli L, Parazzini F, Carrel CF Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol. 2001;44:433–438
  14. Melski JW, Bernhard JD, Stern RS. The Koebner (isomorphic) response in psoriasis: associations with early age of onset and multiple previous therapies. Arch Dermatol. 1983;119:655–659
  15. Naldi L. Psoriasis. In:  Williams HC,  Strachan DP editor. The challenge of dermato-epidemiology. Boca Raton: CRC Press; 1997;p. 175–190
  16. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. In: Clinical epidemiology. A basic science for clinical medicine. 2nd ed.. London: Little Brown and Co; 1991;p. 3–18
  17. Last JM. A dictionary of epidemiology. New York: Oxford University Press; 1988;
  18. Silman AJ, Hochberg MC. Psoriatic arthropathy. In: Epidemiology of the rheumatic diseases. New York: Oxford University Press; 1993;p. 86–104
  19. Campalani E, Barker JNWN. The clinical genetics of psoriasis. Curr Genomics. 2005;6:51–60
  20. Naldi L, Colombo P, Benedetti Placchesi E, et al. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology. 2004;208:38–42
  21. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?. Arch Dermatol. 1996;132:717–718
  22. Sagoo GS, Tazi-Ahnini R, Barker JW, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol. 2004;122:1401–1405
  23. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–632
  24. Kawada A, Tezuka T, Nakamizo Y, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31:59–64
  25. Ohkawara A, Yasuda H, Kobayashi H, et al. Generalised pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76:68–71
  26. Zelickson BD, Muller SA. Generalised pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127:1339–1345
  27. Viguier M, Allez M, Zagdanski AM, et al. High frequency of cholestasis in generalised pustular psoriasis. Evidence for neutrophilic involvement of the biliary tract. Hepatology. 2004;40:452–458
  28. Zachariae H, Overgaard Petersen H, Kissmeye Nielsen F, Lamm L. HL-A antigens in pustular psoriasis. Dermatologica. 1977;154:73–77
  29. Oumeish OY, Parish JL. Impetigo herpetiformis. Clin Dermatol. 2006;24:101–104
  30. Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol. 1997;36:266–271
  31. Saissi EH, Beau-Salinas F, Jonville-Bera AP, Lorette G, Autret-Leca E, Centres Regionaux de Pharmacovigilance . Drugs associated with acute generalized exanthematic pustulosis. Ann Dermatol Venereol. 2003;130:612–618[Article in French]
  32. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) a clinical reaction pattern. J Cutan Pathol. 2001;28:113–119
  33. Rosenberg BE, Strober BE. Acrodermatitis continua. Dermatol Online J. 2004;10:9
  34. O'Doherty CJ, MacIntyre C. Palmoplantar pustulosis and smoking. BMJ. 1985;291:861–864
  35. Enforts W, Molin L. Pustulosis palmaris and plantaris. A follow up study of a ten-year material. Ann Dermatol Venereol. 1971;51:289–294
  36. Kasperczyk A, Freyschmidt J. Pustulotic arthroosteitis: spectrum of bone lesions with palmoplantar pustulosis. Radiology. 1994;191:201–211
  37. Szanto E, Linse U. Arthropathy associated with palmoplantar pustulosis. Clin Rheumatol. 1991;10:130–135
  38. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29:159–171
  39. Balasubramaniam P, Berth-Jones J. Erythroderma: 90% skin failure. Hosp Med. 2004;65:100–102
  40. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7:317–321
  41. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673
  42. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005;141:1601–1602
  43. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–798
  44. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–986
  45. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–267
  46. Choi HK, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177
  47. Naldi L, Chatenoud L. Psoriasis and cancer: more than a chance link. Ann Dermatol Venereol. 2006;133:221–223
  48. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392
  49. Fries JF. Toward an understanding of patient outcome measurement. Arthritis Rheum. 1983;26:697–704
  50. Farber EM, Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:1–18
  51. Katz S. The science of quality of life. J Chron Dis. 1987;40:459–463
  52. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65
  53. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136:305–314
  54. O'Neill P, Kelly P. Postal questionnaire of disability in the community associated with psoriasis. BMJ. 1996;313:919–921
  55. EMEA Committee for Proprietary Medical Products. Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02
  56. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194–199
  57. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–778
  58. Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol. 2006;126:1480–1489
  59. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708
  60. Ros AM, Eklund G, Odont D. Photosensitive psoriasis. An epidemiologic study. J Am Acad Dermatol. 1987;17:752–758
  61. Dunna SF, Finlay AY. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol. 1989;120:584
  62. Kendler KS. Toward a scientific psychiatric nosology: strengths and limitations. Arch Gen Psychiatry. 1990;47:969–973
  63. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324

PII: S0738-081X(07)00147-2

doi: 10.1016/j.clindermatol.2007.08.003

Clinics in Dermatology
Volume 25, Issue 6 , Pages 510-518 , November 2007

Article Tools

* Image Usage & Resolution